Details
The treatment landscape for transthyretin amyloidosis (ATTR) is evolving rapidly, shifting from symptom management to true disease modification.
Key takeaways:
✅ Earlier diagnosis is critical. Once significant nerve or cardiac damage has occurred, current therapies can slow progression but have limited ability to reverse established organ dysfunction.